Up to15% off
Third-party tested
Third-party tested
Growth Hormone Secretagogues
FDA-approved as Egrifta for HIV lipodystrophy
Tesamorelin
Also known as: Egrifta, TH9507
Tesamorelin is a synthetic analog of GHRH (growth hormone-releasing hormone) and the only GHRH analog FDA-approved for clinical use (under the brand name Egrifta, for HIV-associated lipodystrophy). It produces strong, physiologic GH release and is especially noted for reducing visceral (deep belly) fat — making it popular for body recomposition, cognitive benefits, and metabolic health.
Size
Bundle & Save
$90
10mg
Free Xpresspost shipping on orders over $199
Tesamorelin is a synthetic analog of GHRH (growth hormone-releasing hormone) and the only GHRH analog FDA-approved for clinical use (under the brand name Egrifta, for HIV-associated lipodystrophy). It produces strong, physiologic GH release and is especially noted for reducing visceral (deep belly) fat — making it popular for body recomposition, cognitive benefits, and metabolic health.
Third-Party TestedEvery batch verified
Ships from CanadaFast domestic delivery
Free XpresspostOn orders over $199
Secure CheckoutSafe & private
Half-Life
~30 min plasma, but sustained GH/IGF-1 elevation
Common Dose
1–2 mg per day
Route
Subcutaneous injection (abdomen)
Frequency
Once daily
Mechanism of Action
Tesamorelin binds to GHRH receptors on the pituitary, stimulating natural pulsatile GH release. The resulting elevation in GH and IGF-1 supports lipolysis (especially visceral fat breakdown), lean muscle preservation, improved skin and tissue quality, and neurocognitive benefits. Unlike CJC-1295 no DAC, it has a longer half-life and produces stronger sustained GH elevation.
Reported Benefits
- ✦Significant reduction in visceral fat
- ✦Lean muscle preservation/growth
- ✦Improved cognition and memory (studied in HIV patients)
- ✦Better skin elasticity and quality
- ✦Improved sleep and recovery
- ✦Lowered triglycerides
- ✦FDA-approved (in HIV lipodystrophy)
Dosage Protocol
Common dose1–2 mg per day
Range1–2 mg per day (clinical dose is 2 mg/day)
FrequencyOnce daily, typically pre-bed
AdministrationSubcutaneous injection (abdomen)
Notes
Available in 10 mg and 20 mg vials. Reconstitute and handle according to the applicable research protocol. Published safety information recommends monitoring IGF-1 and glucose where appropriate.
Research Status
FDA-approved for HIV lipodystrophy (as Egrifta). Off-label use for general body composition and cognitive benefits.
Storage
Lyophilized: refrigerate. Reconstituted: refrigerate, use within 30 days.
Legal Status
FDA-approved as Egrifta for HIV lipodystrophy. Off-label and research use otherwise.
Dose Calculator
Pre-filled with Tesamorelin's vial size. Enter your water volume and desired dose to see exactly how many units to draw.
Total milligrams in the vial (check the label)
Bacteriostatic water added to reconstitute
Micrograms you want per injection
Insulin syringe capacity
Results
Concentration
—mcg/mL
Volume to Inject
—mL
Draw to Mark
—units
Doses per Vial
—doses
Fill in all fields above to see your results.
Quick Reference
1 mg= 1,000 mcg
1 mL= 100 units (on a 100u syringe)
1 mL= 1 cc
Common reconstitution1–3 mL BAC water per vial
How long will this vial last?
Choose the vial strength, enter the amount used per draw, and add the number of draws per week to estimate how long it will last.
Estimated duration
—
Email me this protocol
Keep a copy of these calculated values for your laboratory records.
This will open your default email app to send the protocol. Automated email delivery can be connected separately.
Research use only. This tool is a mathematical reference for trained laboratory personnel. It does not recommend a dose, injection volume, treatment, or human use. Always follow your approved protocol, product documentation, and applicable regulations.
Explore the catalogue
You may also like
Get 25% off your first order
Drop your email and we’ll unlock a one-time 25% discount code.
Zenova Peptides
For laboratory research purposes only. Not for human use. Not medical advice.